<--- Back to Details
First PageDocument Content
Food and Drug Administration / Clinical research / Pharmaceutical industry / Clinical pharmacology / Artemether / Novartis / New Drug Application / Plasmodium falciparum / Center for Drug Evaluation and Research / Pharmaceutical sciences / Pharmacology / Medicine
Date: 2008-12-01 09:01:37
Food and Drug Administration
Clinical research
Pharmaceutical industry
Clinical pharmacology
Artemether
Novartis
New Drug Application
Plasmodium falciparum
Center for Drug Evaluation and Research
Pharmaceutical sciences
Pharmacology
Medicine

FOOD AND DRUG ADMINISTRATION

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 21,79 KB

Share Document on Facebook

Similar Documents

CENTER FOR DRUG EVALUATION AND RESEARCH DRUG SAFETY PRIORITIES 2017

DocID: 1ueGS - View Document

CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208573Orig1s000 SUMMARY REVIEW

DocID: 1t19G - View Document

CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022526Orig1s000 SUMMARY REVIEW

DocID: 1sZi5 - View Document

MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

DocID: 1sPXO - View Document

Abstract # 2639 Enhanced (Q)SAR Models for Prediction Rodent Carcinogenicity Naomi L. Kruhlak1, Dongyu Guo1, Kevin P. Cross2, Lidiya Stavitskaya1 FDA Center for Drug Evaluation and Research (CDER), 10903 New Hampshire A

DocID: 1swgc - View Document